2
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
FED
1
Study Type
Observational
1
Sponsor
Cancer Type
Sarcoma
1
Plasma cell
1
Conditions
Multiple Myeloma
47
Leukemia, Myeloid, Acute
25
Recurrence
21
Lymphoma, Large B-Cell, Diffuse
13
Sarcoma
9
Lymphoma
6
Neoplasms, Plasma Cell
5
Neoplasm Metastasis
5
Glioblastoma
5
Endometrial Neoplasms
5
Ovarian Neoplasms
4
Neurofibrosarcoma
4
Neoplasms
4
Melanoma
4
Lymphoma, T-Cell, Peripheral
4
Lymphoma, Non-Hodgkin
4
Colorectal Neoplasms
4
Triple Negative Breast Neoplasms
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Myelodysplastic Syndromes
3
Lymphoma, Extranodal NK-T-Cell
3
Lymphoma, B-Cell
3
Liposarcoma
3
Glioma
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma
3
Waldenstrom Macroglobulinemia
2
Thymoma
2
Sarcoma, Alveolar Soft Part
2
Rhabdoid Tumor
2
Interventions
Cyclophosphamide
76
fludarabine phosphate
42
Filgrastim
38
Peripheral Blood Stem Cell Transplantation
35
Radiotherapy
33
Cyclosporine
32
Busulfan
32
Mycophenolic Acid
30
Etoposide
30
Antilymphocyte Serum
28
Whole-Body Irradiation
26
Methotrexate
25
Rituximab
22
Melphalan
21
Methylprednisolone
20
Vincristine
17
Tacrolimus
17
Cytarabine
17
Cord Blood Stem Cell Transplantation
17
Doxorubicin
16
Prednisone
15
Thiotepa
10
Granulocyte Colony-Stimulating Factor
9
Carboplatin
8
Leucovorin
7
fludarabine
6
aldesleukin
6
Ifosfamide
6
sargramostim
5
Sirolimus
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Dendritic Cell Sarcoma, Interdigitating
×
selinexor
×
Clear all
NCT06452446
2025-02-10
Selinexor
Durham VA Medical Center
Active not recruiting
20 enrolled